Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
Around 40% of available marketed drugs are poorly bioavailable or soluble, and about 90% of New Chemical Entities are known for their low solubility and permeabilityLexaria’s patented DehydraTECH(TM) technology offers a solution by improving how APIs (active pharmaceutical ingredients) enter the bloodstreamDehydraTECH achieves this by bypassing first-pass-liver metabolismBy doing so, Lexaria is facilitating faster and much more thorough drug delivery In a report published in…